10/09/2017 Physiogenex will be at the AASLD Liver Meeting 2017
Physiogenex will be attending the AASLD Liver Meeting 2017 in Washington DC, October 20th-24th, 2017.
If you wish to know more about our preclinical NASH models to optimize your preclinical drug development program,
please contact us to set-up an appointment with Dr. François Briand, Director of Research and Business Development during the Liver meeting.
We look forward seeing you in Washington DC!
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information